gdc
Liver Cancer

Lenvima and Keytruda Combination Shows Promise in Patients with Inoperable Liver Cancer

The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable).
ASCO 2020 Highlights
Meg Barbor, MPH

The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable). This drug combination was also shown to be safe, according to the results of a clinical trial presented at the 2020 ASCO annual meeting by Andrew X. Zhu, MD, PhD, Director, Liver Cancer Research, Massachusetts General Hospital, Boston.

“Multi-kinase inhibition with lenvatinib plus PD-1 inhibition with pembrolizumab results in promising anti-tumor activity, as evidenced by a high objective response rate and disease control rate,” Dr. Zhu reported.

Lenvatinib is a targeted therapy that is currently approved by the FDA for the treatment of liver cancer that cannot be removed by surgery in patients who have not received any previous therapy. Pembrolizumab is an immunotherapy that is approved by the FDA for the treatment of liver cancer in patients who have already received treatment with Nexavar (sorafenib), a standard treatment for liver cancer.

Improved Outcomes

In this new study, Dr. Zhu and colleagues evaluated the efficacy and safety of the combination of lenvatinib and pembrolizumab in 100 patients with unresectable liver cancer.

According to Dr. Zhu, by the time of data collection at end of October 2019, 37 of the 100 patients in the study were still receiving treatment, including 34 patients who were receiving the 2 drugs and 3 patients who were receiving lenvatinib alone.

Almost 40% of patients were able to continue treatment with the combination of lenvatinib and pembrolizumab, which suggests that the drugs are safe and tolerable.

“Overall, there were no new or unexpected toxicities resulting from lenvatinib plus pembrolizumab combination therapy,” said Dr. Zhu.

According to the investigators, imaging tests showed that in the majority (more than 80%) of patients the tumor was shrinking, and these reductions continued for many months, between 9 months and 13 months.

In addition, treatment with this combination resulted in about 9 months of no disease progression for these patients. The percentage of patients whose tumors responded to therapy was between 36% and 46%, depending on the method used to measure a response. The disease was controlled, meaning the tumor was reduced or remained stable, in almost 90% of the patients.

Side Effects

After receiving treatment for about 8 months, almost all (95%) of the patients had at least 1 treatment-related side effect. A total of 67% of the patients had a serious (grade 3 or worse) side effect, including 63% with grade 3, 1% with grade 4 side effect, and 3 patients died. The 3 deaths were, 1 each, related to respiratory failure, abnormal liver function, and intestinal perforation (tear in the intestine).

“The most common treatment-related adverse events included hypertension, diarrhea, fatigue, decreased appetite, and hypothyroidism,” Dr. Zhu reported.

“However, most of these were grade 1 or grade 2,” he noted. Grade 1 and 2 side effects are mild and moderate and typically resolve on their own or with minimal management.

A much larger phase 3 clinical trial is currently evaluating the combination of lenvatinib plus pembrolizumab versus lenvatinib alone in patients with unresectable liver cancer. The results of this trial will provide further data on the safety and efficacy of treatment with lenvatinib plus pembrolizumab in this patient population.

Key Points

  • Treatment with lenvatinib plus pembrolizumab is safe and effective for patients with unresectable liver cancer
  • More than 80% of patients with liver cancer had tumor shrinkage, which lasted 9 to 13 months
  • Between 36% and 46% of patients’ tumors responded to the combination treatment
  • In nearly 90% of the patients, the tumor was reduced or remained stable for the length of the study period

Share this:

Recommended For You
Breast Cancer
Tukysa Improves Survival in Patients with HER2-Positive Breast Cancer that Has Spread to the Brain
By Meg Barbor, MPH
The new cancer drug Tukysa (tucatinib), when given in combination with Herceptin (trastuzumab) and capecitabine, dramatically improved outcomes for patients with HER2-positive advanced breast cancer that has spread to the brain, according to data presented by Nancy U. Lin, MD, Associate Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2020 ASCO annual meeting.
Breast Cancer
Adding Kisqali to Endocrine Therapy Increases Survival in Patients with Advanced Breast Cancer and Visceral Metastases
By Meg Barbor, MPH
Metastatic breast cancer is cancer that has spread beyond the breast to other parts of the body. Visceral metastases refer to cancer that has spread to the internal organs of the body, specifically those within the chest (such as the heart or lungs) or abdomen (such as the liver, pancreas, or intestines).
Lung Cancer
Tecentriq Improves Patient-Reported Outcomes in Advanced Non–Small-Cell Lung Cancer
By Meg Barbor, MPH
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy.
Last modified: September 11, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country